|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,211.00 INR | +0.68% |
|
+2.63% | +8.64% |
| 06-17 | Glenmark Pharmaceuticals Launches Methylene Blue Injection in US | MT |
| 06-11 | Glenmark Pharmaceuticals Unit Launches Acne Treatment Winlevi in European Markets | MT |
| Market Cap | 624B 6.55B 5.73B 5.26B 4.91B 9.31B 9.45B 63.2B 24.57B 307B 24.6B 24.07B 1,057B | P/E 2026 |
44.2x | P/E 2027 * | 26.6x |
|---|---|---|---|---|---|
| Enterprise Value | 585B 6.14B 5.37B 4.93B 4.6B 8.72B 8.85B 59.22B 23.02B 287B 23.05B 22.55B 990B | EV / Sales 2026 |
3.51x | EV / Sales 2027 * | 3.52x |
| Free-Float |
51.03% | Yield 2026 |
0.12% | Yield 2027 * | 0.24% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | +0.68% | ||
| 1 week | +2.63% | ||
| Current month | +0.30% | ||
| 1 month | +1.70% | ||
| 3 months | +5.70% | ||
| 6 months | +7.10% | ||
| Current year | +8.64% |
| 1 week | 2,142.8 |  | 2,244.5 |
| 1 month | 2,101 | | 2,252.5 |
| Current year | 1,842 | | 2,474 |
| 1 year | 1,792.6 | | 2,474 |
| 3 years | 649.45 | | 2,474 |
| 5 years | 348.5 | | 2,474 |
| 10 years | 161.65 | | 2,474 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/1999 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 26/05/2025 |
Indrajit Bose
PSD | President | - | 14/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 11/05/2011 | |
| Director/Board Member | 85 | 13/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.68% | +2.63% | +23.97% | +235.28% | 6.55B | |
| +1.81% | +2.25% | +13.40% | +84.45% | 48B | |
| -2.54% | +3.72% | +65.71% | +113.61% | 36.89B | |
| +0.15% | +1.26% | -3.35% | +45.56% | 12.37B | |
| +3.71% | +3.56% | +14.13% | +97.20% | 11.95B | |
| +0.39% | +0.58% | +33.25% | +119.07% | 9.01B | |
| +0.66% | -0.57% | +19.28% | +45.55% | 7.2B | |
| +0.71% | +1.75% | +53.59% | -7.09% | 7.05B | |
| +9.99% | +32.94% | -15.69% | +27.08% | 6.58B | |
| -0.57% | +4.59% | +26.40% | +125.51% | 4.36B | |
| Average | +1.50% | +4.28% | +23.07% | +88.62% | 15B | |
| Weighted average by Cap. | +0.80% | +3.39% | +27.87% | +90.61% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 153B 1.61B 1.41B 1.29B 1.2B 2.28B 2.32B 15.51B 6.03B 75.26B 6.04B 5.91B 259B | 167B 1.75B 1.53B 1.41B 1.31B 2.49B 2.53B 16.9B 6.57B 82.02B 6.58B 6.44B 283B |
| Net income | 20.53B 216M 189M 173M 161M 306M 311M 2.08B 809M 10.09B 809M 792M 34.78B | 23.22B 244M 213M 196M 183M 346M 352M 2.35B 914M 11.41B 915M 896M 39.33B |
| Net Debt | -39.29B -413M -361M -332M -309M -586M -595M -3.98B -1.55B -19.32B -1.55B -1.52B -66.56B | -37.1B -390M -341M -313M -292M -553M -562M -3.76B -1.46B -18.24B -1.46B -1.43B -62.84B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/26 | ₹2,211.00 | +0.68% | 632,010 |
| 02/07/26 | ₹2,196.00 | +1.58% | 526,651 |
| 01/07/26 | ₹2,161.90 | -1.92% | 455,357 |
| 30/06/26 | ₹2,204.30 | +0.81% | 830,485 |
| 29/06/26 | ₹2,186.60 | +1.49% | 1,414,518 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
